Quick Answer
Emmaus Life Sciences, Inc. reported Diluted EPS of $0.12 per share (loss) for fiscal year 2025.
Emmaus Life Sciences, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.12 | -20.0% |
| 2024 | -$0.10 | -42.9% |
| 2023 | -$0.07 | +66.7% |
| 2022 | -$0.21 | +34.4% |
| 2021 | -$0.32 | -128.6% |
| 2013 | -$0.14 | +92.3% |
| 2012 | -$1.81 | +61.8% |
| 2011 | -$4.74 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.03 | -200.0% | -50.0% |
| June 30, 2025 | -$0.02 | +33.3% | +50.0% |
| March 31, 2025 | -$0.04 | +42.9% | -233.3% |
| September 30, 2024 | $0.03 | +400.0% | +200.0% |
| June 30, 2024 | -$0.03 | +0.0% | +57.1% |
| March 31, 2024 | -$0.07 | +0.0% | -600.0% |
| September 30, 2023 | -$0.01 | +0.0% | +66.7% |
| June 30, 2023 | -$0.03 | +83.3% | +57.1% |
- Emmaus Life Sciences, Inc. showed a decrease of -20.0% in Diluted EPS compared to the prior fiscal year.
- Over the 2011–2025 period, Emmaus Life Sciences, Inc.’s diluted eps has grown by 97.5% (from $4.74 per share (loss) to $0.12 per share (loss)).
- The most recent figure is from Emmaus Life Sciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: